Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02114268 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 342
- Enrollment target
NCT02114268: Completed Phase 1 study, sponsored by MedImmune.
NCT02114268 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 342 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (470% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02114268, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 342 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy adult participants.
Primary Outcome
An adverse event (AE) is defined as events present at baseline that worsened in intensity after administration of investigational products or events absent at baseline that emerged after administration of study drug, for the period extending to 391 (Day 361 ± 30 days) days after the last dose of study drug.
Interventions
- DRUG Placebo
- DRUG MEDI8897 Intravenous
- DRUG MEDI8897 Intramuscular
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
What the finished NCT02114268 record still lists
NCT02114268 is an interventional study that assigns participants to a tested intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (470% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02114268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02114268 about?
NCT02114268 is a clinical study titled "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults". The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy adult participants.
What is the current status of trial NCT02114268?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 342 participants. The study started on 2014-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02114268?
The interventions under investigation include: Placebo (DRUG), MEDI8897 Intravenous (DRUG), MEDI8897 Intramuscular (DRUG).
Who is sponsoring clinical trial NCT02114268?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02114268's enrollment target sits among peer trials
342 103rd of 2000 higher than 1,897 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia